TruAlt Bioenergy Ltd Valuation Shifts to Fair Amid Strong Price Gains

Valuation Metrics and Recent Changes

As of 24 April 2026, TruAlt Bioenergy’s price-to-earnings (P/E) ratio stands at 28.40, a figure that has edged higher compared to its historical averages. This increase has contributed to the company’s valuation grade being downgraded from attractive to fair. The price-to-book value (P/BV) ratio has similarly risen to 3.02, signalling a premium over the company’s net asset value that investors are now willing to pay.

Other valuation multiples provide additional context: the enterprise value to EBIT (EV/EBIT) ratio is 23.35, while the enterprise value to EBITDA (EV/EBITDA) ratio is 18.27. These multiples, while elevated, remain below some of the more expensive peers in the commodity chemicals sector, suggesting that TruAlt Bioenergy is not yet overextended but is losing some of its previous valuation appeal.

Peer Comparison Highlights

When compared with key competitors, TruAlt Bioenergy’s valuation appears more moderate. For instance, Navin Fluorine International trades at a P/E of 57.36 and an EV/EBITDA of 34.64, categorised as very expensive. Himadri Speciality Chemical’s P/E ratio is 38.41 with an EV/EBITDA of 28.61, also very expensive. Deepak Nitrite and Atul are rated expensive with P/E ratios of 43.46 and 33.10 respectively.

In contrast, TruAlt Bioenergy’s P/E of 28.40 and EV/EBITDA of 18.27 place it in a more reasonable valuation bracket, albeit no longer in the attractive category. This relative valuation suggests that while the stock has become pricier, it still offers a more accessible entry point compared to the sector’s high flyers.

Financial Performance and Returns

TruAlt Bioenergy’s return on capital employed (ROCE) is 8.87%, and return on equity (ROE) is 10.11%, indicating moderate efficiency in generating profits from capital and shareholder equity. These returns, while respectable, are not exceptional within the sector, which may partly explain the shift in valuation perception.

The stock price has shown robust momentum recently, with a day change of 6.39% and a current price of ₹489.15, up from the previous close of ₹459.75. The 52-week high is ₹550.00, while the low is ₹310.70, reflecting significant volatility over the past year.

In terms of returns relative to the broader market, TruAlt Bioenergy has outperformed the Sensex considerably. Over the past week, the stock returned 16.63% compared to the Sensex’s decline of 0.42%. Over one month, the stock surged 26.62%, dwarfing the Sensex’s 6.83% gain. Year-to-date, TruAlt Bioenergy has gained 21%, while the Sensex has fallen 8.87%. These figures underscore the stock’s strong recent performance despite the valuation adjustment.

Market Capitalisation and Mojo Score

TruAlt Bioenergy is classified as a small-cap company, which inherently carries higher volatility and risk compared to larger, more established firms. Its Mojo Score currently stands at 41.0, reflecting a sell rating. This is an improvement from a previous strong sell grade, which was downgraded on 30 March 2026. The upgrade in rating suggests some stabilisation in the company’s outlook, although caution remains warranted.

The valuation grade change from attractive to fair is consistent with this more cautious stance. Investors should note that while the stock has appreciated sharply in recent months, the premium now demanded by the market limits further upside without corresponding improvements in fundamentals.

Sector and Industry Context

Within the commodity chemicals sector, valuation multiples have generally expanded, driven by rising input costs, supply chain challenges, and shifting demand patterns. TruAlt Bioenergy’s current valuation reflects these broader sector dynamics, where investors are willing to pay more for companies with stable earnings and growth prospects.

However, the company’s PEG ratio remains at 0.00, indicating either a lack of meaningful earnings growth projections or data unavailability. This contrasts with peers such as Himadri Speciality Chemical (PEG 1.13) and Sumitomo Chemical (PEG 7.55), which have higher growth expectations priced in. The absence of a positive PEG ratio may be a factor limiting TruAlt Bioenergy’s valuation expansion.

Investment Implications

For investors, the shift from attractive to fair valuation signals a need to reassess the risk-reward profile of TruAlt Bioenergy. While the stock’s recent price appreciation and outperformance relative to the Sensex are encouraging, the elevated P/E and P/BV ratios suggest that much of the positive sentiment is already priced in.

Comparative analysis with peers indicates that TruAlt Bioenergy remains more reasonably valued, offering a potential entry point for investors seeking exposure to the commodity chemicals sector without paying a premium. However, the company’s moderate returns on capital and equity, combined with the lack of dividend yield, temper enthusiasm.

Outlook and Conclusion

TruAlt Bioenergy Ltd’s valuation adjustment from attractive to fair reflects a maturing market view amid rising multiples and sector-wide valuation expansion. While the company’s recent stock performance has been strong, investors should weigh the premium now embedded in the price against the company’s moderate profitability metrics and growth outlook.

Given the small-cap status and the current Mojo Grade of sell, a cautious approach is advisable. Investors seeking exposure to commodity chemicals may find more compelling opportunities among peers with stronger growth prospects or more attractive valuations. Nonetheless, TruAlt Bioenergy’s relative valuation remains reasonable compared to very expensive sector leaders, offering a balanced risk profile for selective investors.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today